Jump to content

Talk:Modafinil

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia


Drug Tolerance

[edit]

The section on drug tolerance contradicts itself. The first para states that "Extensive clinical research has not demonstrated drug tolerance...."; the next four paras describe development of tolerance! The first para references different cites from the remainder of the section. One would need to check these references rather carefully to see what confidence can be placed in this opening statement, and whether it needs to be qualified. I believe modafinil has a much lower risk of developing tolerance in short-term or occasional use than the amphetamines, but I would be very surprised if it were shown to have no tolerance after 40 weeks of regular use.

The rest of the section is a bit verbose and could be redacted.

I don't have time in the next couple of days to do the edit justice, but I'll keep this on my to do list. As usual, feel free to preempt me ;-) D Anthony Patriarche (talk) 17:09, 10 July 2024 (UTC)[reply]

@D A Patriarche thank you, you have made a good observation. I edited the first paragraph to address your concern. Maxim Masiutin (talk) 18:11, 11 October 2024 (UTC)[reply]

State of this article

[edit]

I don't know about reference bureaucracy in English Wikipedia, but this article now feels like heavy based on critique and make modafinil to sound like as "inferior amphetamine". I would like to remind that is very mild drug in it's psychoactivity, more comparable to caffeine, regardless of drug laws.

Adverse effects like severe allergic reactions is very rare and should be stated as such in introduction. The most common one is headache. While this is abused a lot, there are contradictory research about addiction potential and tolerance to this drug. Even if there is, it's definitely not similar to classic dopamine drugs. Euphoria is more like a rare adverse effect. Probably more people will perceive it as dysphoric from increased anxiety. Also, trying to state stimulant doesn't increase cognitive functioning, is like saying that water isn't wet.

I won't change anything here, just my impression about where this is heading to recent months. --GreenZeb (talk) 07:01, 4 August 2024 (UTC)[reply]

@GreenZeb Better safe than sorry. Maxim Masiutin (talk) 17:59, 11 October 2024 (UTC)[reply]
@GreenZeb I added a clarification that allergic/immunological reactions are rare. Maxim Masiutin (talk) 18:19, 11 October 2024 (UTC)[reply]

Number of references used and page ranges

[edit]

I'm concerned about the number of references which are being used. An innumerable amount of claims in the article are referenced with more than one citation. If both (or three or four) citations confirm the information provided in a statement, then only one should be used. Instances where a certain citation covers only one part of a statement, and a second citation covers a different part of the statement, should always follow WP:INTEGRITY. (I see a few examples of this, but just a few.) Also, the lead section should (ideally) be devoid of references.

Another issue I see is the use of page ranges. Almost every single journal article referenced here gives page ranges rather than a single page where the information exists. During the previous unsuccessful GAR, Maxim Masiutin stated When I refer to particular articles, I read the whole article, not just the abstract. If that was the case, why aren't the exact page numbers used in the citation, rather than using page ranges? The first 7 journal articles used in the References section have a combined page range of 97 pages. Needless to say during a GA review, the nominator ought not be expecting a reviewer to read all 97 pages in order to verify claims which, in all likelihood, appear on only seven of those pages. The better way to do this is to place the exact page number under the |page= parameter, or else use the {{rp}} template. Regards,  Spintendo  19:56, 25 December 2024 (UTC)[reply]

Why do you think that "if both (or three or four) citations confirm the information provided in a statement, then only one should be used"? You referred to WP:TOOMANYREFS, but this page didn't say that. Maxim Masiutin (talk) 20:25, 25 December 2024 (UTC)[reply]

Request on changes to addiction and liability status

[edit]

hi I've been going to school for my degree in chemical depenency, and in my multiple classes I've come to learn that modafinil addiction and dependence liability is no higher than of low status. Armodafinil is another story. this would be on the the moderate side. so I request we change the status to reflect it true state. thank you NW49ERSFAN24 (talk) 00:39, 26 December 2024 (UTC)[reply]

Cite a WP:MEDRS source that support this claim. Please go through the link. --WikiLinuz (talk) 05:40, 26 December 2024 (UTC)[reply]

Clarification on a WP:MEDRS sourced claim that was reverted

[edit]

A recent edit on this Modafinil article was reverted on this article that used a sourced claim, and I raised the issue on a related article to confirm that the source, a PCORI Evidence Update for clinicians, follows WP:MEDRS. In that clarification, both @Doc James and @Bluerasberry provided community feedback that sources such as this follow WP:MEDRS and can thus be included here. Based on this discussion, I will refine and re-add this edit to this article. Thank you. FULBERT (talk) 14:14, 26 December 2024 (UTC)[reply]

The PCORI source is not adequate for the statement and is neither vetted by peer-review nor is it mainstream clinical practice (therefore, not MEDRS). It is simply a summary of limited primary research on the off-label combination of modafinil and amantadine, which increased adverse events mentioned in one part of the report. It should not be used in the article. Zefr (talk) 15:47, 26 December 2024 (UTC)[reply]